Evidence map›Paper›PMID 41618119›Full record

Observational studyCancer science2026

Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.

Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, Motohiro Tamiya, Kazumi Nishino, Akihiro Tamiya, Kyoichi Okishio, Yuhei Kinehara, Tomoki Kuge, Masahide Mori and 11 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Kinnosuke MatsumotoDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0002-4930-6997
Yujiro NaitoDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Takayuki ShiroyamaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Motohiro TamiyaDepartment of Respiratory Medicine, Osaka International Cancer Institute, Osaka, Japan.
Kazumi NishinoDepartment of Respiratory Medicine, Osaka International Cancer Institute, Osaka, Japan.
Akihiro TamiyaDepartment of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Osaka, Japan.ORCID https://orcid.org/0000-0003-3599-2583
Kyoichi OkishioDepartment of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Osaka, Japan.
Yuhei KineharaDepartment of Respiratory Medicine and Clinical Immunology, Nippon Life Hospital, Osaka, Japan.
Tomoki KugeDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Masahide MoriDepartment of Thoracic Oncology, NHO Osaka Toneyama Medical Center, Osaka, Japan.
Shingo SatohDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Hidekazu SuzukiDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Satoshi TetsumotoDepartment of Respiratory Medicine and Clinical Immunology, Suita Municipal Hospital, Osaka, Japan.
Toshie NikiDepartment of Respiratory Medicine, Nishinomiya Municipal Central Hospital, Nishinomiya, Japan.
Yasuhiko SugaDepartment of Respiratory Medicine, Osaka Keisatsu Hospital, Osaka, Japan.
Akio OsaDepartment of Respiratory Medicine, Kinki Central Hospital, Itami, Japan.
Toshiyuki MinamiDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.ORCID https://orcid.org/0000-0001-7421-8457
Shohei KoyamaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0002-6897-9417
Yoshito TakedaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Nobuyuki TakakuraDepartment of Signal Transduction, Research Institute for Microbial Diseases, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0003-0397-8605
Atsushi KumanogohDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.

Funding

Eli Lilly JapanJapan Agency for Medical Research and Development 25ama221533h0002Japan Science and Technology Agency JPMJSP2138Japan Society for the Promotion of Science 20H05698Ministry of Education, Culture, Sports, Science and Technology JPMXP1323015484Support for Pioneering Research Initiated by the Next Generation
6 · The paper itself

Abstract

Ramucirumab plus docetaxel (RAM+DOC) demonstrates clinical activity after programmed cell death-1 (PD-1) inhibitors in advanced non-small cell lung cancer (NSCLC); however, the underlying mechanisms remain unclear. We aimed to evaluate clinical efficacy and explore immunologic dynamics and benefit-associated biomarkers. Patients treated with RAM+DOC after PD-1 inhibitors were enrolled in a multicenter prospective cohort. Anti-PD-1 antibody bound (IgG4

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDocetaxelImmune Checkpoint InhibitorsLung NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedProgrammed Cell Death 1 ReceptorProgression-Free SurvivalProspective StudiesRamucirumabAntibodies, Monoclonal, HumanizedDocetaxelImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorRamucirumabnivolumabNSCLCpembrolizumabramucirumabsequential

Identifiers

PMID41618119
PMCPMC13045383

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.